Stent to treat pancreatic cysts approved

December 19, 2013

(HealthDay)—The Axios Stent and Delivery System has been approved by the U.S. Food and Drug Administration to treat infected pancreatic cysts that won't drain on their own and could become life threatening, the FDA said in a news release.

The pancreas, found in the upper abdomen behind the stomach, produces insulin that helps regulate and helps digestion. If pancreatic ducts become blocked from gallstones or injury, enzymes that back up into the organ can cause formation of pancreatic pseudocysts.

Most resolve on their own, but some become infected and can lead to a life-threatening blood infection, the FDA said.

The Axios stent is a wire mesh tube that can expand to more than 1/2-inch diameter. It was evaluated among 33 clinical study participants who had a pancreatic pseudocyst at least six centimeters in diameter. Some 86 percent of pseudocysts treated shrank by half or more, the FDA said.

The most common side effects of the stent included , nausea and vomiting.

The device is produced by Xlumena Inc. of Mountain View, Calif.

Explore further: Study examines endoscopic ultrasound-guided drainage of pancreatic pseudocysts

More information: Visit Medline Plus to learn more about pancreatic pseudocysts.

Related Stories

Two pancreatic-enzyme products approved

March 2, 2012

(HealthDay) -- Two drugs that supplement the digestion-aiding actions of pancreatic enzymes have been approved by the U.S. Food and Drug Administration, the agency said Thursday in a news release.

Imbruvica approved for mantle cell lymphoma

November 13, 2013

(HealthDay)—Imbruvica (ibrutinib) has been approved by the U.S. Food and Drug Administration to treat mantle cell lymphoma (MCL), a rare but aggressive form of blood cancer.

Signifor approved for Cushing's disease

December 17, 2012

(HealthDay)—Signifor (pasireotide diaspartate) has been approved by the U.S. Food and Drug Administration to treat Cushing's disease in cases that cannot be treated by surgery.

Gattex approved for short bowel syndrome

December 22, 2012

(HealthDay)—Gattex (teduglutide) has been approved by the U.S. Food and Drug Administration to treat nutritional problems caused by short bowel syndrome.

Recommended for you

Researchers identify source of opioids' side effects

January 17, 2017

A commercially available drug may help drastically reduce two side effects of opioid painkillers—a growing tolerance and a paradoxical increased sensitivity to pain—without affecting the drugs' ability to reduce pain, ...

CVS generic competitor to EpiPen, sold at a 6th the price

January 12, 2017

CVS is now selling a rival, generic version of Mylan's EpiPen at about a sixth of its price, just months after the maker of the life-saving allergy treatment was eviscerated before Congress because of its soaring cost to ...

Many misuse OTC sleep aids: survey

December 29, 2016

(HealthDay)—People struggling with insomnia often turn to non-prescription sleep remedies that may be habit-forming and are only intended for short-term use, according to a new Consumer Reports survey.

The pill won't kill your sexual desire, researchers say

December 15, 2016

Taking the pill doesn't lower your sexual desire, contrary to popular belief, according to research published in the Journal of Sexual Medicine. The authors of the research, from the University of Kentucky and Indiana University ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.